Cover Image
市場調查報告書

製藥產業上季度交易分析:聯盟、許可證、投資、M&A與趨勢

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2017

出版商 GlobalData 商品編碼 242636
出版日期 內容資訊 英文 89 Pages
訂單完成後即時交付
價格
Back to Top
製藥產業上季度交易分析:聯盟、許可證、投資、M&A與趨勢 Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2017
出版日期: 2017年07月03日 內容資訊: 英文 89 Pages
簡介

本報告提供全球製藥、醫療市場相關資料每季相關調查分析,尤其是以聯盟、許可證、M&A、資金籌措相關主要資料與趨勢分析為焦點,提供過去5季交易數量交易類型/市場區隔/各地區比較與交易額,製藥、醫療產業的主要創業投資(VC)和顧問公司最新資訊,為您概述為以下內容。

第1章 目錄

第2章 全球製藥、醫療市場:交易摘要

  • M&A
  • 股票上市交易
  • 創業投資交易
  • 私募股權的發行

第3章 全球製藥、醫療市場:聯盟交易

  • 聯盟交易
  • 聯盟交易:各治療領域
  • 聯盟交易:預付款/階段性付款、各交易金額
  • 聯盟交易:各治療領域,預付款/階段性付款、各交易金額
  • 聯盟交易:各階段,交易數量、交易額
  • 聯盟交易:各階段,預付款/階段性付款、各交易金額

第4章 全球製藥、醫療市場:授權合約

  • 授權合約
  • 授權合約交易:預付款/階段性付款、交易額
  • 授權合約交易:各治療領域,總交易額
  • 授權合約交易:各治療領域,預付款vs.階段性付款
  • 授權合約交易:各階段,總交易額
  • 授權合約交易:各階段,預付款vs.階段性付款

第5章 全球製藥、醫療市場:M&A財務分析

  • 平均交易額vs.中間交易額
  • 被收購企業的平均股票價格收益
  • 被收購企業的平均EV/EBITA
  • 每項營業利益的平均交易額
  • 每股的平均交易額vs.每股的平均市場價格
  • 每股的平均交易額vs.每股的平均賬面價格
  • 每銷售的平均交易額

第6章 全球製藥、醫療市場:交易摘要(各治療領域)

  • 腫瘤
  • 中樞神經系統
  • 感染疾病
  • 免疫系
  • 代謝障礙
  • 心血管系統
  • 消化管
  • 皮膚科
  • 呼吸系統
  • 眼科

第7章 交易摘要(各地區)

  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第8章 全球製藥、醫療市場:主要的投資顧問公司

  • M&A:過去1年
  • 股票上市:過去1年

第9章 附錄

第10章 其他資訊

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC513QD

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2017", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q1 2017. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

The pharmaceutical and healthcare industry reported a decrease in the number of deals and an increase in deal values in Q1 2017 with 1,142 deals worth USD95.5 billion, as compared 1,165 worth USD91.4 billion in Q1 2016. On a quarter-on-quarter basis, the number of deals and deal values increased in Q1 2017, when compared to 1,082 deals worth USD84.3 billion in Q4 2016. The pharmaceutical and healthcare industry reported a decrease in upfront payments in licensing agreements with USD731m in Q1 2017, as compared USD1.3 billion in Q1 2016. On a quarter-on-quarter basis, the upfront payments reported a decrease in Q1 2017, when compared to USD1 billion in Q4 2016. Deals in oncology therapeutics market registered an increase with 421 deals in Q1 2017, compared to 356 deals in Q4 2016.

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the five quarters.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 5
  • 1.2 List of Figures 7

2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q1 2017 10

  • 2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q1 2017 10
  • 2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q1 2017 12
  • 2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q1 2017 13
  • 2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q1 2017 14
    • 2.4.1 Johnson & Johnson to Acquire Actelion for USD30 Billion 14
    • 2.4.2 Takeda Pharma Acquires Ariad Pharma for up to USD5.2 Billion in Tender Offer 15
    • 2.4.3 Pfizer Raises USD4.2 Billion in Public Offering of Notes 15
    • 2.4.4 Royalty Pharma Acquires Royalty Stream of Tysabri from Perrigo for USD2.85 Billion 16
    • 2.4.5 Fresenius Raises USD2.7 Billion in Private Placement of Notes 16

3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 17

  • 3.1 Pharmaceuticals & Healthcare, Global, M&A, Q1 2017 17
    • 3.1.1 Top M&A Deals in Q1 2017 18
    • 3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q1 2016 - Q1 2017 19
  • 3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q1 2017 20
    • 3.2.1 Top Initial Public Offerings in Q1 2017 21
    • 3.2.2 Top Secondary Offerings in Q1 2017 21
    • 3.2.3 Top PIPE Deals in Q1 2017 22
    • 3.2.4 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q1 2016 - Q1 2017 23
  • 3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q1 2017 24
    • 3.3.1 Top Venture Financing Deals in Q1 2017 25
    • 3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q1 2017 26
    • 3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q1 2017 26
    • 3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q1 2016 - Q1 2017 28
    • 3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q1 2016 - Q1 2017 29
    • 3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q1 2016 - Q1 2017 30
  • 3.4 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q1 2017 31
    • 3.4.1 Top Private Equity Deals in Q1 2017 32
    • 3.4.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q1 2016 - Q1 2017 33

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q1 2017 34

  • 4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q1 2017 34
  • 4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q1 2016 - Q1 2017 35
  • 4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2017 36
    • 4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q1 2017 37
    • 4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q1 2017 37
    • 4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q1 2017 38
  • 4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2016 - Q1 2017 39
  • 4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q1 2016 - Q1 2017 40
  • 4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q1 2016 - Q1 2017 41
  • 4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2016 - Q1 2017 42

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q1 2017 44

  • 5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q1 2017 44
  • 5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2016 - Q1 2017 45
    • 5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q1 2017 46
    • 5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q1 2017 46
    • 5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q1 2017 47
  • 5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q1 2016 - Q1 2017 48
  • 5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q1 2016 - Q1 2017 49
  • 5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q1 2016 - Q1 2017 50
  • 5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q1 2016 - Q1 2017 51
  • 5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q1 2016 - Q1 2017 52

6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 54

  • 6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q1 2017 54
    • 6.1.1 Oncology - Deals of the Quarter 55
  • 6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q1 2017 56
    • 6.2.1 Central Nervous System - Deals of the Quarter 57
  • 6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q1 2017 59
    • 6.3.1 Infectious Disease - Deals of the Quarter 60
  • 6.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q1 2017 61
    • 6.4.1 Immunology - Deals of the Quarter 62
  • 6.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q1 2017 63
    • 6.5.1 Metabolic Disorders - Deals of the Quarter 64
  • 6.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q1 2017 65
    • 6.6.1 Cardiovascular - Deals of the Quarter 66
  • 6.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q1 2017 67
    • 6.7.1 Gastrointestinal - Deals of the Quarter 68
  • 6.8 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q1 2017 70
    • 6.8.1 Ophthalmology - Deals of the Quarter 71
  • 6.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q1 2017 72
    • 6.9.1 Respiratory - Deals of the Quarter 73
  • 6.10 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q1 2017 74
    • 6.10.1 Dermatology - Deals of the Quarter 75

7 Deal Summary by Geography 77

  • 7.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q1 2017 77
    • 7.1.1 North America - Deals of the Quarter 78
  • 7.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q1 2017 79
    • 7.2.1 Europe - Deals of the Quarter 80
  • 7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q1 2017 81
    • 7.3.1 Asia-Pacific - Deals of the Quarter 82
  • 7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q1 2017 83
    • 7.4.1 Rest of the World - Deals of the Quarter 84

8 Pharmaceuticals & Healthcare, Global, Top Advisors 85

  • 8.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q1 2016 - Q1 2017 85
  • 8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q1 2016 - Q1 2017 86

9 Further Information 87

  • 9.1 Methodology 87
  • 9.2 About GlobalData 88
  • 9.3 Contact Us 88
  • 9.4 Disclosure information 88
  • 9.5 Disclaimer 89

List of Tables

1.1 List of Tables

  • Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q1 2016 - Q1 2017 11
  • Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q1 2017 13
  • Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q1 2017 14
  • Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 17
  • Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q1 2017 18
  • Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q1 2016 - Q1 2017 19
  • Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2016 - Q1 2017 21
  • Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q1 2017 21
  • Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q1 2017 21
  • Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q1 2017 22
  • Table 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2016 - Q1 2017 23
  • Table 12: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 24
  • Table 13: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q1 2017 25
  • Table 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q1 2017 27
  • Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2016 - Q1 2017 28
  • Table 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 29
  • Table 17: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q1 2016 - Q1 2017 30
  • Table 18: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 31
  • Table 19: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q1 2017 32
  • Table 20: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2016 - Q1 2017 33
  • Table 21: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 34
  • Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 35
  • Table 23: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2016 - Q1 2017 36
  • Table 24: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2017 37
  • Table 25: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q1 2017 37
  • Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q1 2017 38
  • Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q1 2016 - Q1 2017 39
  • Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2016 - Q1 2017 41
  • Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2016 - Q1 2017 43
  • Table 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 44
  • Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2016 - Q1 2017 45
  • Table 32: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q1 2017 46
  • Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q1 2017 46
  • Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q1 2017 47
  • Table 35: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 48
  • Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q1 2016 - Q1 2017 49
  • Table 37: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2016 - Q1 2017 51
  • Table 38: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2016 - Q1 2017 53
  • Table 39: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 55
  • Table 40: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 57
  • Table 41: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 60
  • Table 42: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 62
  • Table 43: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 64
  • Table 44: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 66
  • Table 45: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 68
  • Table 46: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 71
  • Table 47: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 73
  • Table 48: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 75
  • Table 49: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 78
  • Table 50: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 80
  • Table 51: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 82
  • Table 52: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 84
  • Table 53: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 85
  • Table 54: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 86

List of Figures

1.2 List of Figures

  • Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q1 2016 - Q1 2017 10
  • Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q1 2017 12
  • Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q1 2017 13
  • Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q1 2016 - Q1 2017 17
  • Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q1 2016 - Q1 2017 19
  • Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 20
  • Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q1 2016 - Q1 2017 23
  • Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 24
  • Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q1 2017 26
  • Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q1 2017 26
  • Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q1 2016 - Q1 2017 28
  • Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 29
  • Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 31
  • Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q1 2016 - Q1 2017 33
  • Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 34
  • Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 35
  • Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q1 2016 - Q1 2017 36
  • Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q1 2016 - Q1 2017 39
  • Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2016 - Q1 2017 40
  • Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2016 - Q1 2017 41
  • Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2016 - Q1 2017 42
  • Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 44
  • Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2016 - Q1 2017 45
  • Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 48
  • Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2016 - Q1 2017 49
  • Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q1 2016 - Q1 2017 50
  • Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q1 2016 - Q1 2017 51
  • Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2016 - Q1 2017 52
  • Figure 29: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 54
  • Figure 30: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 56
  • Figure 31: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 59
  • Figure 32: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 61
  • Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 63
  • Figure 34: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 65
  • Figure 35: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 67
  • Figure 36: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 70
  • Figure 37: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 72
  • Figure 38: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 74
  • Figure 39: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 77
  • Figure 40: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 79
  • Figure 41: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 81
  • Figure 42: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 83
  • Figure 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 85
  • Figure 44: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 86
Back to Top